Pulmonary tuberculosis during the developmental period contributes to COPD and pre-COPD in mid-to-late adulthood: a retrospective cohort study
Therapeutic Advances in Respiratory Disease · Published 2026-05-01 · DOI 10.1177/17534666261445203
Free full text
Authors being retrieved — see the publisher record. https://doi.org/10.1177/17534666261445203
Abstract
Background: The effect of non-smoking factors on Chronic Obstructive Pulmonary Disease (COPD) is gaining attention. Long-term contributions of pulmonary tuberculosis (PTB) during the developmental period to COPD development in later adulthood remain poorly understood. Objectives: To investigate the impact of PTB during the developmental period of COPD and pre-COPD. Design: Retrospective cohort study Methods: This retrospective cohort study analyzed 496,534 participants using the UK Biobank cohort. PTB during the developmental period was defined as a diagnosis at age ⩽25 years. Outcomes were COPD and pre-COPD stages, including preserved ratio impaired spirometry (PRISm) and impaired spirometry (below Lower Limit of Normal (LLN) thresholds). Associations were evaluated using the multivariable logistic regression, adjusting for age, sex, body mass index, smoking, asthma, bronchiectasia, and air pollution. Results: Among 10,178 patients (62 (9) years old) diagnosed with COPD, PTB during the developmental period was statistically associated with increased COPD risk across four models, showing a fully adjusted odds ratio (aOR) of 1.82 (95% CI: 1.45–2.26), and remained significant regardless of sex or smoking status. Critically, PTB was also independently associated with both PRISm and airflow obstruction (aOR = 1.52, 95% CI: 1.35–1.71) and impaired spirometry below LLN (aOR = 1.32, 95% CI: 1.14–1.52). Sensitivity analyses further reinforced the robustness of these findings. Conclusion: PTB during the developmental period is an independent risk factor for COPD and pre-COPD status in mid-to-late adulthood, necessitating long-term respiratory monitoring in PTB during the developmental period survivors and the implementation of targeted public health strategies.
Abstract from DOAJ. Public domain (CC0 1.0).
Read the article at the publisher →
Publication details
- Year
- 2026
Related articles
- Advances in orphan drug development for alpha-1 antitrypsin deficiency: a 2025 update from the FDA and EMA · Therapeutic Advances in Respiratory Disease · 2026 · Same journal
- Assessment of efficacy and tolerability of elexacaftor-tezacaftor-ivacaftor in an observational cohort study of “aged” people with cystic fibrosis · Therapeutic Advances in Respiratory Disease · 2026 · Same journal
- The effectiveness of the AI-based RehabLung mobile rehabilitation system on cardiopulmonary function and user satisfaction in lung cancer patients undergoing thoracic surgery: a protocol for a two-arm randomized clinical trial · Therapeutic Advances in Respiratory Disease · 2026 · Same journal
- Spontaneous pneumothorax-associated with genetic disorders · Therapeutic Advances in Respiratory Disease · 2026 · Same journal
- Randomized, phase I studies to evaluate the safety, tolerability, and pharmacokinetics of an inhaled, TMEM16A potentiator, GDC-6988, in healthy subjects · Therapeutic Advances in Respiratory Disease · 2025 · Same journal
- Effects of dual bronchodilation on right ventricular function and troponin-I in newly diagnosed, moderate-to-severe chronic obstructive pulmonary disease: a prospective real-world observational study · Therapeutic Advances in Respiratory Disease · 2026 · Same journal
- Bioequivalence of budesonide/glycopyrrolate/formoterol fumarate with a next-generation propellant versus hydrofluoroalkane-134a in healthy adults: phase I, randomized, double-blind, single-dose, partial-replicate, three-way cross-over lung exposure and total systemic exposure studies · Therapeutic Advances in Respiratory Disease · 2026 · Same journal
- Social risk factors in patients with cystic fibrosis: impacts on exacerbations, lung function, and BMI · Therapeutic Advances in Respiratory Disease · 2025 · Same journal
- Tislelizumab in conjunction with chemotherapy for the treatment of nasal metastasis from lung squamous cell carcinoma: a case report and literature review · Therapeutic Advances in Respiratory Disease · 2025 · Same journal
- The association between mental health, cognitive functioning, and health-related quality of life in adults with chronic nontuberculous mycobacterial pulmonary disease · Therapeutic Advances in Respiratory Disease · 2025 · Same journal